DESTINY-Breast03 Phase 3 Study Results
Antitumor Responses
Responses observed regardless of PD-L1 expression
Best change from baseline
in target lesion size (%)
100-
N=29
50-
0
-50-
-100-
Patients evaluable for
confirmed response"
Confirmed ORR, n (%)
27
20 (74)
95% CI
54-89
CR, n (%)
2 (7)
PR, n (%)
18 (67)
+
t
Daiichi-Sankyo
◆ Confirmed ORR
was observed in
20/27 (74%)
patients
PD-L1 expression (TAP 5% cutoff):
Data cutoff: November 15, 2021
ESMO BC 2022 #166 Mini Oral
High
ILow
aHad the opportunity to have 2 postbaseline scans.
Unknown/Missing
Dotted lines indicate thresholds for partial response (-30%) and progressive disease (20%).
*If the best percentage change from baseline of target lesions cannot be calculated due to progression, withdrawal, or death, the value is imputed at +20%.
"." Patients with PD as best overall response. †CR with lymph node disease (CR per RECIST in lymph nodes, is <10mm). ‡ Unconfirmed response.
CR, complete response; ORR, objective response rate; PR, partial response.
77View entire presentation